Allergan And Editas Medicine Announce Dosing Of First Patient In Landmark Phase 1/2 Clinical Trial Of CRISPR Medicine AGN-151587 (EDIT-101) For The Treatment Of LCA10

by bizlift | Mar 4, 2020 | Editas Press Releases, Portfolio News

Twist Bioscience Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

by bizlift | Feb 24, 2020 | Portfolio News, Twist Press Releases

Denali Therapeutics Announces Pricing of Public Offering of Common Stock

by bizlift | Jan 29, 2020 | Denali Press Releases, Portfolio News

Building on Momentum: AiCure Announces Leadership Changes and New President

by bizlift | Jan 28, 2020 | AiCure Press Releases, Portfolio News

Twist Bioscience Announces Completion of $50 Million Registered Direct Offering Priced At-The-Market

by bizlift | Jan 27, 2020 | Portfolio News, Twist Press Releases

BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders

by bizlift | Jan 23, 2020 | BlackThorn Press Releases, Portfolio News